As of Thursday close, Revolution Medicines Inc.’s (NASDAQ:RVMD) stock was up $0.75, moving up 2.52 percent to $30.48. The average number of shares traded per day over the past five days has been 1,834,440 shares. 1 time new highs have been achieved over the past 5 days, with a -$2.07 fall in that time frame. In the last twenty days, the average volume was 1,185,595, while in the previous 50 days, it was 1,108,228.
Since last month, RVMD stock retreated -0.07%. Shares of the company fell to $29.45 on 09/21/23, the lowest level in the past month. A 52-week high of $35.50 was reached on 09/05/23 after having rallying from a 52-week low of $17.03. Since the beginning of this year, RVMD’s stock price has risen by 27.96% or $6.66, and marked a new high 13 times. However, the stock has declined by -14.14% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
RVMD stock investors should be aware that Revolution Medicines Inc. (RVMD) stock had its last reported insider trading activity 4 days ago on Sep 18. GOLDSMITH MARK A, the of the company, disposed of 8,054 shares for $31.31 on Sep 18. It resulted in a $252,175 divestment by the insider. Horn Margaret A sold 2,514 shares at an average price of $31.31 on Sep 18. The insider now owns 96,960 shares following the transaction. On Sep 18, Kelsey Stephen Michael sold 2,060 shares at $31.31 apiece. The transaction was valued at $64,500.
Valuation Metrics
The stock’s beta is 1.38. Besides these, the trailing price-to-sales (P/S) ratio of 115.61, the price-to-book (PB) ratio of 3.50.
Financial Health
In the three months ended June 29, Revolution Medicines Inc.’s quick ratio stood at 11.80, while its current ratio was 11.80, showing that the company is able to pay off its debt. Based on annual data, RVMD earned $293.66 million in gross profit and brought in $35.38 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -37.60%. Return on equity (ROE) for the past 12 months was -36.50%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. RVMD’s revenue fell -138.74% to $7.01 million during the quarter, while net income inched up to $3.82 million. While analysts expected Revolution Medicines Inc. to report -$0.82 quarterly earnings, the actual figure was -$0.92 per share, beating the consensus estimate by -12.20%. During the quarter, the company generated -$111.88 million in EBITDA. The liabilities of Revolution Medicines Inc. were 142.87 million at the end of its most recent quarter ended June 29, and its total debt was $63.26 million. The value of shareholders’ equity is $109.17 million.
Technical Picture
This quick technical analysis looks at Revolution Medicines Inc.’s (RVMD) price momentum. With a historical volatility rate of 33.10%, the RSI 9-day stood at 38.66% on 21 September.
With respect to its five-day moving average, the current Revolution Medicines Inc. price is down by -6.36% percent or -$2.07. At present, RVMD shares trade -2.40% below its 20-day simple moving average and +29.76% percent above its 100-day simple moving average. However, the stock is currently trading approximately +13.14% above its SMA50 and +19.39% above its SMA200.
Stochastic coefficient K was 8.73% and Stochastic coefficient D was 6.56%, while ATR was 1.18. Given the Stochastic reading of 17.02% for the 14-day period, the RSI (14) reading has been calculated as 44.46%. As of today, the MACD Oscillator reading stands at -1.27, while the 14-day reading stands at -1.85.
Analyst Ratings
JP Morgan upgraded its rating on Revolution Medicines Inc. (NASDAQ: RVMD) to an Overweight in a note to investors on February 28, 2023. The analysts firm previously had a Neutral rating on the stock.Revolution Medicines Inc. (RVMD) has been rated Buy by analysts. According to 0 brokerage firms, RVMD is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Revolution Medicines Inc. stock as buy, with 7 recommending it as overweight.
With a median target price of $34.00, the current consensus forecast for the stock is $30.00 – $47.00. Based on these forecasts, analysts predict Revolution Medicines Inc. (RVMD) will achieve an average price target of $36.71.
